Format

Send to

Choose Destination
Rheumatol Int. 2012 Feb;32(2):295-9. doi: 10.1007/s00296-011-2096-3. Epub 2011 Sep 1.

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.

Author information

1
Swedish Orphan Biovitrum AB, 11276 Stockholm, Sweden. Christina.Kaiser@sobi.com

Abstract

Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of anakinra is to competitively inhibit the local inflammatory effects of IL-1. Kineret is generally safe and well tolerated and the only major treatment-related side effects that appear are skin reactions at the injection site. Due to the relatively short half-life of anakinra, daily injection of the drug is required. This, in combination with the comparably high rates of injection-site reactions (ISRs) associated with the drug, can become a problem for the patient. The present review summarises published data concerning ISRs associated with Kineret and provides some explanations as to their cause. The objective is also to present some clinical experiences of how the ISRs can be managed.

PMID:
21881988
PMCID:
PMC3264859
DOI:
10.1007/s00296-011-2096-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center